- Home
- OSBC vs PVLA Comparison
OSBC vs PVLA Comparison
Compare OSBC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSBC | PVLA |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 952.7M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OSBC | PVLA |
|---|---|---|
| Price | $19.82 | $99.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $21.63 | ★ $124.25 |
| AVG Volume (30 Days) | ★ 275.3K | 258.9K |
| Earning Date | 01-21-2026 | 11-11-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $288,832,000.00 | N/A |
| Revenue This Year | $27.16 | N/A |
| Revenue Next Year | $12.26 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $14.14 | $11.17 |
| 52 Week High | $20.14 | $106.71 |
Technical Indicators
Market Signals| Indicator | OSBC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 69.54 | 61.41 |
| Support Level | $18.88 | $90.09 |
| Resistance Level | $19.75 | $102.04 |
| Average True Range (ATR) | 0.45 | 7.43 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 85.32 | 62.87 |
Price Performance
Historical ComparisonAbout OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.